Search research articles
Contact Us
Filters
Showing results (381-390 of 501) with videos related to
Page
of 51
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 19, 2014
Circulating CD4+ T cells that produce IL4 or IL17 when stimulated by melan-A but not by NY-ESO-1 have negative impacts on survival of patients with stage IV melanoma
Henning Zelba, Benjamin Weide, Alexander Martens, et al.
Theranostics
|
January 7, 2020
Cancer immunotherapy is accompanied by distinct metabolic patterns in primary and secondary lymphoid organs observed by non-invasive <i>in vivo</i><sup>18</sup>F-FDG-PET
Johannes Schwenck, Barbara Schörg, Francesco Fiz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 6, 2017
Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma
Jason Chesney, Igor Puzanov, Frances Collichio, et al.
Cancers
|
July 3, 2020
Pimasertib Versus Dacarbazine in Patients With Unresectable <i>NRAS</i>-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover
Celeste Lebbé, Caroline Dutriaux, Thierry Lesimple, et al.
Pigment Cell & Melanoma Research
|
April 8, 2014
In melanoma, Hippo signaling is affected by copy number alterations and YAP1 overexpression impairs patient survival
Moritz Menzel, Diana Meckbach, Benjamin Weide, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 21, 2022
COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With <i>BRAF</i> V600-Mutant Melanoma
Reinhard Dummer, Keith T Flaherty, Caroline Robert, et al.
Der Hautarzt; Zeitschrift Fur Dermatologie, Venerologie, Und Verwandte Gebiete
|
September 6, 2019
[Dermatoscopy-30 years after the First Consensus Conference]
Andreas Blum, Friedrich A Bahmer, Jürgen Bauer, et al.
The New England Journal of Medicine
|
September 30, 2014
Combined vemurafenib and cobimetinib in BRAF-mutated melanoma
James Larkin, Paolo A Ascierto, Brigitte Dréno, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 23, 2021
5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study
Paolo A Ascierto, Brigitte Dréno, James Larkin, et al.
Pigment Cell & Melanoma Research
|
August 8, 2009
Meeting report: consensus from the first and second Global Workshops in Melanoma November 19-20, 2008
Sanjiv S Agarwala, Jurgen C Becker, Alexander M Eggermont, et al.
Page
of 51
Search research articles
Search
Showing results (381-390 of 501) with videos related to
Sort By:
Page
of 51
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 19, 2014
Circulating CD4+ T cells that produce IL4 or IL17 when stimulated by melan-A but not by NY-ESO-1 have negative impacts on survival of patients with stage IV melanoma
Henning Zelba, Benjamin Weide, Alexander Martens, et al.
Theranostics
|
January 7, 2020
Cancer immunotherapy is accompanied by distinct metabolic patterns in primary and secondary lymphoid organs observed by non-invasive <i>in vivo</i><sup>18</sup>F-FDG-PET
Johannes Schwenck, Barbara Schörg, Francesco Fiz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 6, 2017
Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma
Jason Chesney, Igor Puzanov, Frances Collichio, et al.
Cancers
|
July 3, 2020
Pimasertib Versus Dacarbazine in Patients With Unresectable <i>NRAS</i>-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover
Celeste Lebbé, Caroline Dutriaux, Thierry Lesimple, et al.
Pigment Cell & Melanoma Research
|
April 8, 2014
In melanoma, Hippo signaling is affected by copy number alterations and YAP1 overexpression impairs patient survival
Moritz Menzel, Diana Meckbach, Benjamin Weide, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 21, 2022
COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With <i>BRAF</i> V600-Mutant Melanoma
Reinhard Dummer, Keith T Flaherty, Caroline Robert, et al.
Der Hautarzt; Zeitschrift Fur Dermatologie, Venerologie, Und Verwandte Gebiete
|
September 6, 2019
[Dermatoscopy-30 years after the First Consensus Conference]
Andreas Blum, Friedrich A Bahmer, Jürgen Bauer, et al.
The New England Journal of Medicine
|
September 30, 2014
Combined vemurafenib and cobimetinib in BRAF-mutated melanoma
James Larkin, Paolo A Ascierto, Brigitte Dréno, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 23, 2021
5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study
Paolo A Ascierto, Brigitte Dréno, James Larkin, et al.
Pigment Cell & Melanoma Research
|
August 8, 2009
Meeting report: consensus from the first and second Global Workshops in Melanoma November 19-20, 2008
Sanjiv S Agarwala, Jurgen C Becker, Alexander M Eggermont, et al.
Page
of 51